News About: Pharm. Affairs
Impossibility to coexist between antidiabetic DPP-4 and SGLT-2
The product groups, which have currently attracted the most interests of the domestic diabetes market, are the ‘SGLT-2 inhibitor’ type and the ‘DPP-4 inhibitors’ type.
Domestic influential pharmaceutical companies t...
KPA responds to the notification of card fee raise on pharmacies
The pharmaceutical association has started to respond to unexpected notifications of credit card companies to raise fees.
On the 7th, the Korean Pharmaceutical Association(President Chan-hui Cho, KPA) pressed the Fin...
“Yearly 4-injection schizophrenia treatment is expected to be approved this year”
Schizophrenia is expected to be managed by injection 4 times a year.
Janssen Korea is currently taking the approval procedure of ‘Invega Sustenna(paliperidone, monthly injection), the only domestic long-acting inject...
BMS returned license of anticancer Taxol
BMS Pharmaceutical Korea declared a separation from co-promotion of anticancer Taxol with Boryung Pharm, as well as Baraclude.
According to the industry concerned on the 4th, BMS Pharmaceutical Korea returned the lic...
Domestic biosimilar market will exceed USD 100 million by 2019
The domestic biosimilar market is expected to exceed USD 100 million by 2019.
The Biotech Policy Research Center expected the Korea biosimilar market will grow in the 7.8% CAGR from USD 70 million in 2012 to USD 120 ...
Domestic avian influenza vaccine acquired approval, competing against the GSK’s product
An avian influenza vaccine developed by the domestic technology of Green Cross was approved by the Ministry of Food and Drug Safety(MFDS). It was the first time for a domestic avian vaccine to be approved; thus, depen...
Antidiabetic Suganon acquires approval as a complex
Dong-A ST, which developed Suganon(evogliptin), a domestic DPP-4 inhibitor, has quickly acquired approval of ‘Sugamet,’ a complex of evogliptin and metformin. It has only been 3 months since the approval of Suganon on...
Competition is expected to be activated between ‘Gardasil’ and ‘Cervarix’
Due to the NIP expansion, the competition between the two cervical cancer vaccines, ‘Gardasil’ and ‘Cervarix,’ will get fiercer.
The Ministry of Health and Welfare(MOHW), recently, announced that it added the ‘cervic...
‘Zydena,’ a domestic erectile dysfunction treatment’ with shocking decrease in supply price
The supply price of ‘Zydena,’ a domestic erectile dysfunction treatment developed and marketed by Dong-A ST, will be significantly decreased from the New Year.
It seems the action of the company to secure competitive...
Obligation of long-term tracking on stem cell treatments, improving safety
The government will strengthen safety management, such as obligation of long-term tracking on stem cell treatments.
On the 30th, the Ministry of Food and Drug Safety(MFDS) made the contents above through an official ...
